Asterias Biotherapeutics (AST) Tops Q2 EPS by 7c

August 15, 2016 4:59 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Asterias Biotherapeutics (NYSE: AST) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $1.14 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment